FTO Antibody

What is FTO and why is it an important research target?

FTO is an RNA demethylase that mediates oxidative demethylation of different RNA species, including mRNAs, tRNAs, and snRNAs. It functions as a regulator of fat mass, adipogenesis, and energy homeostasis . FTO specifically demethylates N(6)-methyladenosine (m6A) RNA, the most prevalent internal modification of messenger RNA (mRNA) in higher eukaryotes . The gene was first identified through genome-wide association studies (GWAS) as an obesity-associated gene, and growing evidence suggests it confers increased obesity risk through subtle changes in food intake and preference . Its relevance extends beyond metabolism to cancer biology, particularly in acute myeloid leukemia where FTO inhibition shows therapeutic potential .

What types of FTO antibodies are available for research applications?

Several types of FTO antibodies are available for research, each with specific applications and characteristics:

The choice of antibody depends on the specific experimental design, target tissue/cells, and detection method .

How should FTO antibody be validated before experimental use?

Proper validation of FTO antibodies is critical for experimental reliability. A recommended validation protocol includes:

• RNA interference assessment: Verify antibody specificity using siRNA-mediated knockdown of FTO in cell lines (e.g., HeLa cells). Western blot analysis comparing control vs. siRNA FTO samples should show significant reduction in band intensity at ~58 kDa .

• Knockout (KO) testing: Use CRISPR/Cas9 FTO knockout cells as negative controls .

• Cross-reactivity evaluation: Test antibody against multiple species if cross-species experiments are planned, as reactivity varies between antibodies .

• Application-specific validation: For each application (WB, IHC, IF, etc.), optimize conditions separately as dilution requirements differ significantly:

  • Western Blotting: 1:1000-1:10000 depending on antibody

  • Immunohistochemistry: 1:200-1:2000

  • Immunofluorescence: 1:50-1:500

• Molecular weight confirmation: Verify that the detected protein band appears at the expected molecular weight (58-60 kDa) .

What are the recommended protocols for FTO antibody-based Western blotting?

For optimal Western blotting results with FTO antibodies:

• Sample preparation:

  • Extract proteins using RIPA lysis buffer from tissues or cells

  • Load 20 μg of protein per lane for reliable detection

• Electrophoresis conditions:

  • Use SDS-polyacrylamide gels (8-10% recommended for 58 kDa FTO protein)

  • Include positive control samples (e.g., HeLa, HEK-293T, or SH-SY5Y cell lysates)

• Transfer and blocking:

  • Transfer to PVDF or nitrocellulose membrane

  • Block with protein-free rapid-blocking buffer

• Antibody incubation:

  • Primary antibody dilution: 1:1000-1:3000 for polyclonal (27226-1-AP) , 1:2000-1:10000 for recombinant (81471-1-RR)

  • Incubate overnight at 4°C

  • Use β-Actin (1:5000) as loading control

• Detection and quantification:

  • Visualize using appropriate secondary antibodies and detection system

  • Quantify band density using Image J software

How does FTO subcellular localization affect experimental design and data interpretation?

FTO exhibits differential subcellular localization that significantly impacts experimental design and interpretation:

• Nuclear vs. cytoplasmic distribution:

  • FTO predominantly localizes to the nucleus in many cell types, but shows cytoplasmic localization in specific contexts

  • Overexpression of FTO increases its nuclear localization

• Experimental considerations:

  • Cell fractionation is recommended to distinguish nuclear vs. cytoplasmic FTO functions

  • For immunofluorescence, paraformaldehyde fixation (4%, 10 min) followed by permeabilization with 0.1% PBS-Tween (20 min) works effectively for SH-SY5Y cells

• Tissue-specific expression patterns:

  • Western blot analysis in porcine tissues shows high FTO expression in cerebellum, salivary gland, kidney, and spleen; low expression in duodenum, jejunum, thyroid, and adrenal gland; and lowest expression in pancreas, liver, skeletal muscles, and adipose tissue

  • Consider these expression differences when selecting appropriate positive control tissues

• Impact on data interpretation:

  • Differential subcellular localization suggests distinct functions in different cellular compartments

  • Researchers should correlate localization data with functional readouts to accurately interpret FTO's role in cellular processes

  • The hypothalamus shows particularly high FTO expression, consistent with its role in regulating energy balance and appetite

How can researchers effectively use FTO antibodies in CLIP-seq experiments to study FTO-RNA interactions?

For effective CLIP-seq experiments to study FTO-RNA interactions:

• Antibody selection and validation:

  • Verify antibody specificity for immunoprecipitation (IP) applications

  • Use at least two different antibodies (e.g., anti-FTO and anti-Flag for FTO-Flag tagged protein) to minimize antibody-specific artifacts

• Control strategies:

  • Include appropriate IgG controls

  • Compare normal cells vs. FTO-overexpressing cells

  • Consider including a positive control CLIP (e.g., PTBP1)

• Crosslinking and immunoprecipitation protocol:

  • After UV crosslinking, perform immunoprecipitation with anti-FTO antibodies

  • Excise gel regions containing protein-RNA complexes above the molecular weight of FTO/FTO-Flag for sequencing library preparation

  • For validation, perform UV-RIP-PCR analysis on anti-FTO enriched RNA fragments

• Data analysis considerations:

  • FTO binding peaks analysis shows that at basal expression levels, the majority of FTO binding (46.43%-50.59%) occurs in intronic regions

  • Upon FTO overexpression, binding peaks preferentially shift to protein coding regions

  • Compare CLIP data with m6A methylation patterns to correlate binding with demethylation activity

• Technical challenges:

  • Be aware that FTO CLIP data typically yields a low fraction of usable reads

  • FTO overexpression increases the usable reads fraction, which may influence experimental design decisions

How should researchers approach seemingly contradictory data regarding FTO expression in different cancer types?

When confronting contradictory data regarding FTO in cancer research:

What are the optimal experimental conditions for detecting FTO-mediated RNA demethylation changes?

To effectively detect FTO-mediated RNA demethylation:

• RNA isolation considerations:

  • Separate analysis of different RNA species (mRNA, small RNA) is essential as FTO may affect them differently

  • For example, FTO silencing impacts m6Am/A ratio in mRNA but not in small RNA species

• Analytical methods and controls:

  • LC-MS/MS provides quantitative measurement of m6A/A and m6Am/A ratios

  • Include positive controls (e.g., METTL14 silencing should decrease m6A levels)

  • For m6Am detection, consider that FTO specifically demethylates the N(6)-methyladenosine at the second transcribed position of mRNAs

• Experimental design factors:

  • FTO overexpression vs. knockdown: Both approaches provide complementary insights

  • FTO localization affects substrate accessibility: Consider nuclear vs. cytoplasmic demethylation targets

  • Time-course experiments may be necessary to capture dynamic demethylation processes

• Target specificity considerations:

  • FTO demethylates multiple RNA modifications including:

    • N(6)-methyladenosine (m6A) in mRNA and U6 snRNA

    • N(6),2'-O-dimethyladenosine cap (m6Am)

    • N(1)-methyladenine in various tRNAs

  • Design appropriate RNA substrates to differentiate between these activities

What methodological considerations are important when using FTO antibodies in diagnostic biomarker research?

When employing FTO antibodies in biomarker research:

• Statistical model selection and validation:

  • Random Forest (RF) models have shown better performance than Support Vector Machine (SVM) models for diagnostic biomarker identification using m6A regulators including FTO

  • Evaluate model performance using:

    • Residual analysis via boxplots and reverse cumulative distribution

    • ROC curve analysis with AUC value assessment

    • Error rate determination through decision trees

• Multi-protein panel approach:

  • Consider FTO alongside other m6A regulators (e.g., HNRNPC, HNRNPA2B1) for improved diagnostic accuracy

  • Utilize Gini coefficient method to identify importance scores of variables in biomarker panels

• Tissue-specific considerations:

  • For conditions like endometriosis, use paired normal and pathological tissue samples

  • Standardize protein extraction and detection methods for consistent results across samples

• Technical protocol details:

  • For Western blot analysis in biomarker research:

    • Use RIPA lysis buffer for protein extraction

    • Load 20 μg protein per lane

    • For FTO detection, use 1:2000 dilution (Abclonal antibody)

    • Use β-Actin (1:5000) as internal control

    • Analyze band densities with Image J software

• PPI network analysis:

  • Integrate FTO with interacting proteins through STRING or similar tools

  • Evaluate PPI enrichment p-values and clustering coefficients to strengthen biomarker validity

How can researchers address non-specific bands when using FTO antibodies in Western blotting?

To resolve non-specific bands in FTO Western blotting:

• Antibody selection:

  • Choose antibodies reported to show good specificity without non-specific bands, such as those noted in product validation data

  • Consider recombinant antibodies (e.g., 81471-1-RR) which often provide higher specificity

• Optimization strategies:

  • Titrate antibody dilutions (1:1000-1:10000 range) to find optimal signal-to-noise ratio

  • Modify blocking conditions (try different blocking buffers)

  • Adjust incubation times and temperatures for primary antibody binding

  • Increase washing stringency with higher detergent concentrations or additional wash steps

• Validation approaches:

  • Use siRNA knockdown controls to confirm specific bands

  • Include positive control lysates from cells known to express FTO (HeLa, HEK-293T, SH-SY5Y)

  • Compare results with multiple FTO antibodies targeting different epitopes

• Technical considerations:

  • Ensure proper sample preparation to prevent protein degradation

  • Verify expected molecular weight (58-60 kDa) for FTO protein

  • Consider tissue-specific expression patterns when interpreting results

What are the key considerations for using FTO antibodies in multi-protein co-immunoprecipitation studies?

For effective multi-protein co-immunoprecipitation with FTO antibodies:

• Antibody selection for IP applications:

  • Not all FTO antibodies are suitable for immunoprecipitation

  • Validated antibodies for IP include polyclonal rabbit antibodies (e.g., 27226-1-AP)

  • Consider antibody format: unconjugated antibodies are typically used for IP

• Experimental design considerations:

  • Crosslinking may be necessary to capture transient interactions

  • RNase treatment controls can differentiate between direct protein-protein interactions versus RNA-mediated associations

  • Use appropriate lysis buffers to maintain protein complex integrity

• Controls and validation:

  • Include IgG negative controls

  • Perform reverse co-IP to confirm interactions

  • Validate interactions with orthogonal methods (e.g., proximity ligation assay)

• Application-specific protocols:

  • For RNA-binding protein interactions (RIP), specific protocols have been validated with FTO antibodies

  • For co-IP specifically targeting FTO-interacting proteins, optimize washing conditions to maintain specific interactions while reducing background

• Data interpretation:

  • Consider FTO's multiple cellular roles when interpreting interaction partners

  • Analyze whether interactions occur in nuclear or cytoplasmic compartments

  • Evaluate whether interactions depend on FTO's enzymatic activity using catalytically inactive mutants as controls

How can researchers effectively incorporate FTO antibodies in drug discovery and validation studies?

For drug discovery targeting FTO:

• Target engagement assays:

  • Use FTO antibodies to develop cellular thermal shift assays (CETSA) to confirm direct binding of small molecules to FTO

  • Employ antibodies in immunofluorescence studies to track changes in FTO localization upon drug treatment

• Functional readouts:

  • Utilize FTO antibodies in Western blot analyses to correlate target inhibition with:

    • Changes in global m6A and m6Am levels

    • Downstream protein expression effects

    • Phenotypic outcomes (e.g., differentiation in AML cells)

• Validation strategy:

  • Combine genetic approaches (siRNA, CRISPR) with pharmacological inhibition

  • Example: FB23-2 (FTO inhibitor) mimics FTO depletion effects, suppressing proliferation and promoting differentiation/apoptosis of AML cells both in vitro and in xenograft models

• Experimental design considerations:

  • Include selective inhibitors (e.g., FB23, FB23-2) that directly bind to FTO and specifically inhibit its m6A demethylase activity

  • Design structure-activity relationship studies with antibody-based readouts

  • Develop mechanism-based assays that measure FTO catalytic activity rather than just expression levels

How should researchers interpret differences in experimental outcomes between genetic FTO knockdown and antibody-based FTO detection systems?

When reconciling differences between genetic manipulation and antibody-based detection:

• Mechanistic explanations for discrepancies:

  • Genetic knockdown/knockout affects the entire protein and all its functions

  • Antibodies may detect specific epitopes that are differentially exposed in various functional states

  • Post-translational modifications may affect antibody recognition without altering expression levels

• Methodological considerations:

  • Temporal differences: genetic knockdown has delayed effects compared to direct protein inhibition

  • Compensatory mechanisms may develop in knockdown systems but not in acute inhibition scenarios

  • Antibody accessibility issues in complex tissue environments versus cell culture models

• Validation approach:

  • Use multiple antibodies targeting different FTO epitopes

  • Combine transcript-level measurements (qPCR) with protein detection

  • Employ activity-based assays to correlate FTO enzymatic function with expression levels

• Experimental design recommendations:

  • Include appropriate controls for each method (siRNA negative controls, isotype antibody controls)

  • Use dose-response and time-course analyses to capture dynamic changes

  • Consider rescue experiments to confirm specificity of observed effects